(-)-Quinpirole hydrochloride

Pricing Availability   Qty
Description: Selective D2-like agonist
Chemical Name: (4aR-trans)-4,4a,5,6,7,8,8a,9-Octahydro-5-propyl-1H-pyrazolo[3,4-g]quinoline hydrochloride
Purity: ≥98% (HPLC)
Citations (39)
Reviews (2)
Literature (2)

Biological Activity for (-)-Quinpirole hydrochloride

(-)-Quinpirole hydrochloride is a selective dopamine D2 receptor agonist (Ki values are 4.8, ~24, ~30 and 1900 nM at D2, D3, D4 and D1 receptors respectively).

Licensing Information

Sold with the permission of Eli Lilly and Company

Compound Libraries for (-)-Quinpirole hydrochloride

(-)-Quinpirole hydrochloride is also offered as part of the Tocriscreen 2.0 Max. Find out more about compound libraries available from Tocris.

Technical Data for (-)-Quinpirole hydrochloride

M. Wt 255.79
Formula C13H21N3.HCl
Storage Desiccate at -20°C
Purity ≥98% (HPLC)
CAS Number 85798-08-9
PubChem ID 55397
Smiles Cl.[H][C@]12CCCN(CCC)[C@]1([H])CC1=CNN=C1C2

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for (-)-Quinpirole hydrochloride

Solvent Max Conc. mg/mL Max Conc. mM
water 25.58 100
DMSO 6.39 25

Preparing Stock Solutions for (-)-Quinpirole hydrochloride

The following data is based on the product molecular weight 255.79. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.91 mL 19.55 mL 39.09 mL
5 mM 0.78 mL 3.91 mL 7.82 mL
10 mM 0.39 mL 1.95 mL 3.91 mL
50 mM 0.08 mL 0.39 mL 0.78 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for (-)-Quinpirole hydrochloride

Certificate of Analysis / Product Datasheet
Select another batch:

References for (-)-Quinpirole hydrochloride

References are publications that support the biological activity of the product.

Levant et al (1996) Modulation of [3H]quinpirole binding in brain by monoamine oxidase inhibitors: evidence for a potential novel binding site. J.Pharmacol.Exp.Ther. 278 145 PMID: 8764345

Seeman and Van Tol (1994) DA receptor pharmacology. Trends Pharmacol.Sci. 15 264 PMID: 7940991

Sullivan et al (1998) Effects of quinpirole on central DA systems in sensitized and non-sensitized rats. Neuroscience 83 781 PMID: 9483561

If you know of a relevant reference for (-)-Quinpirole hydrochloride, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Non-selective Dopamine Agonists

Keywords: (-)-Quinpirole hydrochloride, (-)-Quinpirole hydrochloride supplier, Selective, D2-like, agonists, Dopamine, Non-Selective, Receptors, dopaminergic, Non-selective, 1061, Tocris Bioscience

39 Citations for (-)-Quinpirole hydrochloride

Citations are publications that use Tocris products. Selected citations for (-)-Quinpirole hydrochloride include:

Borgs et al (2016) DArgic neurons differentiating from LRRK2 G2019S induced pluripotent stem cells show early neuritic branching defects. Scientific Reports 6 33377 PMID: 27640816

Picton et al (2016) Mechanisms underlying the endogenous DArgic inhibition of spinal locomotor circuit function in Xenopus tadpoles. Scientific Reports 6 35749 PMID: 27760989

Pedersen et al (2021) A novel luminescence-based-β-arrestin recruitment assay for unmodified receptors. J Biol Chem 296 100503 PMID: 33684444

Ahmadiantehrani and Ron (2013) DA D2 receptor activation leads to an up-regulation of glial cell line-derived neurotrophic factor via Gβγ-Erk1/2-dependent induction of Zif268. J Neurochem PMID: 23373701

Dai et al (2018) Selective blockade of spinal D2DR by levo-corydalmine attenuates MOR tolerance via suppressing PI3K/Akt-MAPK signaling in a MOR-dependent manner. Exp Mol Med 50 148 PMID: 30429454

Zhang (2018) DA Receptor Subtypes Mediate Opposing Effects on Form Deprivation Myopia in Pigmented Guinea Pigs. Invest Ophthalmol Vis Sci 59 4441 PMID: 30193315

Luque-Rojas et al (2013) Hyperactivity induced by the DA D2/D3 receptor agonist quinpirole is attenuated by inhibitors of endocannabinoid degradation in mice. Int J Neuropsychopharmacol 16 661 PMID: 22647577

Snyder et al (2017) Inhibiting clathrin-mediated endocytosis of the leucine-rich G protein-coupled receptor-5 diminishes cell fitness. J Biol Chem 292 7208 PMID: 28275053

Leng et al (2017) Activation of DRD5 inhibits tumor growth by autophagic cell death. Autophagy 13 1404 PMID: 28613975

Tozzi et al (2015) Endogenous 17β-OE is required for activity-dependent long-term potentiation in the striatum: interaction with the DArgic system. Front Cell Neurosci 9 192 PMID: 26074768

Verharen et al (2019) Differential contributions of striatal dopamine D1 and D2 receptors to component processes of value-based decision making. Neurophsychopharmacology 44 2195 PMID: 31254972

Melis et al (2004) Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area DA neurons through activation of CB1 receptors. J Neurosci 24 53 PMID: 14715937

Marchese et al (2003) Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. Br J Pharmacol 140 520 PMID: 12970091

Choi (2017) Role of DA D2 receptor in stress-induced myelin loss. Sci Rep 7 11654 PMID: 28912499

Akoume et al (2019) A Differential Hypofunctionality of Gαi Proteins Occurs in Adolescent Idiopathic Scoliosis and Correlates with the Risk of Disease Progression. Sci Rep 9 10074 PMID: 31296888

Leyrer-Jackson (2017) Subtype-specific effects of DArgic D2 receptor activation on synaptic trains in layer V pyramidal neurons in the mouse prefrontal cortex. Physiol Rep 5 e13499 PMID: 29150590

Spulber et al (2014) PFOS induces behavioral alterations, including spontaneous hyperactivity that is corrected by dexamfetamine in zebrafish larvae. PLoS One 9 e94227 PMID: 24740186

Dorst et al (2020) Polysynaptic inhibition between striatal cholinergic interneurons shapes their network activity patterns in a dopamine-dependent manner. Nat Commun 11 5113 PMID: 33037215

González-Maeso et al (2007) Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior. PLoS One 53 439 PMID: 17270739

Hutchinson et al (2012) Differential regulation of MeCP2 phosphorylation in the CNS by DA and serotonin. Eur J Neurosci 37 321 PMID: 21956448

Hook et al (2012) DArgic modulation of ganglion-cell photoreceptors in rat. Autophagy 35 507 PMID: 22304466

Ferraro et al (2012) A novel mechanism of cocaine to enhance DA d2-like receptor mediated neurochemical and behavioral effects. An in vivo and in vitro study. J Neurosci 37 1856 PMID: 22453136

Lassus et al (2018) Glutamatergic and dopaminergic modulation of cortico-striatal circuits probed by dynamic calcium imaging of networks reconstructed in microfluidic chips. Sci Rep 8 17461 PMID: 30498197

Xing et al (2015) DA D1 receptor activation regulates the expression of the estrogen synthesis gene aromatase B in radial glial cells. Neuropsychopharmacology 9 310 PMID: 26388722

Wang et al (2015) A pivotal role of FOS-mediated BECN1/Beclin 1 upregulation in DA D2 and D3 receptor agonist-induced autophagy activation. Proc Natl Acad Sci U S A 11 2057 PMID: 26649942

Shin et al (2015) Muscarinic regulation of DA and glutamate transmission in the nucleus accumbens. Nat Neurosci 112 8124 PMID: 26080439

Zapata et al (2007) Regulation of DA transporter function and cell surface expression by D3 DA receptors. J Biol Chem 282 35842 PMID: 17923483

Kitada et al (2007) Impaired DA release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci U S A 104 11441 PMID: 17563363

Matsui and Alvarez (2018) Cocaine Inhibition of Synaptic Transmission in the Ventral Pallidum Is Pathway-Specific and Mediated by Serotonin. Cell Rep 23 3852 PMID: 29949769

Jain et al (2018) Melanotan II causes hypothermia in mice by activation of mast cells and stimulation of histamine 1 receptors. Am J Physiol Endocrinol Metab 315 E357 PMID: 29812984

Beas et al (2018) The locus coeruleus drives disinhibition in the midline thalamus via a dopaminergic mechanism. Nat Neurosci 21 963 PMID: 29915192

Gantz et al (2011) Loss of Mecp2 in substantia nigra DA neurons compromises the nigrostriatal pathway. J Neurosci 31 12629 PMID: 21880923

Chuhma et al (2009) DA neuron glutamate cotransmission: frequency-dependent modulation in the mesoventromedial projection. Neuroscience 164 1068 PMID: 19729052

Napolitano et al (2010) Role of aberrant striatal DA D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine. J Neurosci 30 11043 PMID: 20720111

Burgess et al (2010) DArgic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep 33 1295 PMID: 21061851

Higley and Sabatini (2010) Competitive regulation of synaptic Ca2+ influx by D2 DA and A2A adenosine receptors. Nat Neurosci 13 958 PMID: 20601948

Yoon et al (2011) Wnt5a-DA D2 receptor interactions regulate DA neuron development via extracellular signal-regulated kinase (ERK) activation. Neuropsychopharmacology 286 15641 PMID: 21454669

Deng et al (2010) MeCP2 in the nucleus accumbens contributes to neural and behavioral responses to psychostimulants. J Biol Chem 13 1128 PMID: 20711186

Goffin et al (2010) DA-dependent tuning of striatal inhibitory synaptogenesis. Neuron 30 2935 PMID: 20181591

Do you know of a great paper that uses (-)-Quinpirole hydrochloride from Tocris? Please let us know.

Reviews for (-)-Quinpirole hydrochloride

Average Rating: 5 (Based on 2 Reviews.)

5 Star
4 Star
3 Star
2 Star
1 Star

Have you used (-)-Quinpirole hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:

Inhibition of Synaptic Transmission in the VP.
By Anonymous on 02/02/2020
Assay Type: In Vivo
Species: Mouse

quinpirole(1 μΜ)

PMID: 29949769
review image

Quinpirole reduces evoked dopamine release.
By Anonymous on 03/28/2018
Assay Type: Ex Vivo
Species: Mouse

Voltammetry experiments were used to measure evoked dopamine release. Quinpirole (30nM) reduces dopamine release considerably (near IC50 in dorsal striatum), which was reversed by sulpiride (600nM). Drug works every time!

Goes into water well. We usually make up a 1 mM stock for many experiments.

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Dopamine Receptors Scientific Review

Dopamine Receptors Scientific Review

Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.